RNAZ White background cropped.jpg
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
29. November 2024 16:25 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
RNAZ White background cropped.jpg
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
27. November 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
RNAZ White background cropped.jpg
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
25. November 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
RNAZ White background cropped.jpg
TransCode Therapeutics Open Letter to Shareholders
12. November 2024 07:00 ET | TransCode Therapeutics, Inc.
Open Letter to Shareholders
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
05. November 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
23. Oktober 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
RNAZ White background cropped.jpg
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
10. Oktober 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
RNAZ White background cropped.jpg
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17. September 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
10. September 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
RNAZ White background cropped.jpg
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05. September 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate